Savara (SVRA) Free Cash Flow (2010 - 2026)
Savara (SVRA) posted quarterly Free Cash Flow of -$33.1 million for Q1 2026, down 21.73% year-over-year from -$42.3 million in Q1 2025, and down 32.09% quarter-over-quarter from -$25.1 million in Q4 2025.
Powered by 
Analysis
Savara (SVRA) Free Cash Flow (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Free Cash Flow for 17 consecutive years, with -$33.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 21.73% year-over-year to -$33.1 million; the TTM figure through Mar 2026 stood at -$107.0 million (down 11.83% YoY), while the FY2025 annual figure was -$101.1 million, down 13.41% from the prior year.
- Free Cash Flow slipped to -$33.1 million in Q1 2026 per SVRA's latest filing, from -$25.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$8.2 million in Q3 2022 and bottomed at -$33.1 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$18.2 million across 5 years, with a median of -$20.7 million in 2024.
- Annual changes were most pronounced in 2022 — Free Cash Flow increased 23.6% — and 2024, when it plunged 114.5%.
- Savara's Free Cash Flow stood at -$8.7 million in 2022, then slumped by 80.64% to -$15.6 million in 2023, then tumbled by 48.92% to -$23.3 million in 2024, then decreased by 7.68% to -$25.1 million in 2025, then slumped by 32.09% to -$33.1 million in 2026.
- Business Quant data shows SVRA's Free Cash Flow at -$33.1 million in Q1 2026, -$25.1 million in Q4 2025, and -$22.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - | -29.98 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -29.98 Mn |
| Mar 31, 2026 | -33.10 Mn |
| Dec 31, 2025 | -25.04 Mn |
| Sep 30, 2025 | -22.55 Mn |
| Jun 30, 2025 | -26.28 Mn |
| Mar 31, 2025 | -27.19 Mn |
| Dec 31, 2024 | -23.27 Mn |
| Sep 30, 2024 | -22.67 Mn |
| Jun 30, 2024 | -22.52 Mn |
| Mar 31, 2024 | -20.65 Mn |
| Dec 31, 2023 | -15.63 Mn |
| Sep 30, 2023 | -13.20 Mn |
| Jun 30, 2023 | -10.50 Mn |
| Mar 31, 2023 | -12.03 Mn |
| Dec 31, 2022 | -8.65 Mn |
| Sep 30, 2022 | -8.17 Mn |
| Jun 30, 2022 | -9.32 Mn |
| Mar 31, 2022 | -8.43 Mn |
| Dec 31, 2021 | -9.40 Mn |
| Sep 30, 2021 | -8.94 Mn |